Literature DB >> 16710855

Histological recurrent hepatitis C after liver transplantation: Outcome and role of retransplantation.

Giorgio Ercolani1, Gian Luca Grazi, Matteo Ravaioli, Massimo Del Gaudio, Matteo Cescon, Giovanni Varotti, Giovanni Ramacciato, Gaetano Vetrone, Matteo Zanello, Antonio Daniele Pinna.   

Abstract

Impact of hepatitis C virus (HCV) recurrence on long-term outcome after orthotopic liver transplantation (OLT) is highly variable, and the role of retransplantation is still debated. From 1996 to 2003, 131 OLT with histologically proven HCV recurrence and 6 months of follow-up were retrospectively reviewed. One and 5-yr overall survivals were 90.7 and 81.3%, respectively. The mean time of HCV recurrence was 10.1 +/- 6.2 months in patients whose donor's age was less than 70 yr old, and 6.6 +/- 4.7 in patients whose donor's age was more than 70 (P < 0.01). The mean time between OLT and HCV recurrence was 10.7 +/- 8.2 months among patients still alive, and 5 +/- 4.2 among the 20 who died (P = 0.02). In 16 (12.2%) patients, retransplantation was required for severe HCV recurrence; 5 are still alive and 11 (68.7%) died. The mean survival time was 16.2 +/- 6 months if re-OLT was performed within 12 months from first OLT, and it was 45.9 +/- 10 months if re-OLT was performed later (P < 0.01). In conclusion, donors older than 70 yr are at high risk of early HCV recurrence; expectancy of life is significantly reduced in case of histologically proven recurrence within 6 months. Outcome is quite dismal in patients with early HCV recurrence requiring retransplantation within 1 yr of first OLT. Copyright 2006 AASLD

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16710855     DOI: 10.1002/lt.20725

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  3 in total

Review 1.  What is expected from the pathologist in the diagnosis of viral hepatitis?

Authors:  Helmut Denk
Journal:  Virchows Arch       Date:  2011-02-26       Impact factor: 4.064

2.  Retransplantation for graft failure in chronic hepatitis C infection: a good use of a scarce resource?

Authors:  Ian A Rowe; Kerri M Barber; Rhiannon Birch; Elinor Curnow; James M Neuberger
Journal:  World J Gastroenterol       Date:  2010-10-28       Impact factor: 5.742

3.  Antiviral therapy for hepatitis C in the setting of liver transplantation.

Authors:  Gregory T Everson; Clark C Kulig
Journal:  Curr Treat Options Gastroenterol       Date:  2006
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.